A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
This study aimed to (1) confirm efficacy of CBP501/cisplatin/nivolumab for metast atic PDAC observed in a previous phase 1 study, (2) identify combinations that yield 35% 3-month progression-free survival rate (3MPFS) and (3) define the contribution of CBP501 to the effects of combination therapy.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: T. Enzler, A. Nguyen, J. Misleh, V.J. Cline, M. Johns, N. Shumway, S. Paulson, R. Siegel, T. Larson, W. Messersmith, D. Richards, J. Chaves, E. Pierce, M. Zalupski, V. Sahai, D. Orr, S.A. Ruste, A. Haun, T. Kawabe Tags: Original Research Source Type: research